Petr Kavan
Dr. Kavan is currently a medical oncologist practicing at the Jewish General Hospital and McGill University Health Center and has been since 2000. He completed his medical school training at Charles University in Prague, Czech Republic and completed his internship/residency in Pediatrics and Medicine at Charles University Medical School. After that he completed his fellowship in Oncology at the same university in Prague. He was later a visiting fellow and scientist at the Texas Children’s Cancer Center, Baylor College of Medicine, in Houston, USA and a visiting scientist for a short time in: Memphis, USA; Hannover, Germany; Leeds, UK; Paris, France; and Vancouver, British Columbia. He completed his PhD in Oncology Bone Marrow Transplants in 2001.
His honors and awards include: Czech Ministry of Health Award for Grant 0765-5: Late Effects in Pediatric Oncology; the Josef Hlavka Literary Award for the Book of the Year: Bone Marrow Transplantation, and an Adolescent and Young Adult Cancer Award 2010 for lectures and publications. He has also presented at 93 invited lectures within the European Union, the U.S.A. and other international meetings; and more than 130 lectures in Canada since 2007. Dr. Kavan also has 51 peer reviewed publications and 117 poster presentations since 2007, and 5 monographies and 5 CME educational programs since 2008. Dr. Kavan is a member of many national and international cancer organizations, including ASCO and ESMO. He also serves as a reviewer of publications, presentations and grants. Dr. Kavan is the principle or co-investigator of 11 large research grants received since 2003.
Gastrointestinal Oncology with neuroendocrine tumors and GIST included as well as Neurooncology
His current clinical specialties are Gastrointestinal Oncology with neuroendocrine tumors and GIST included as well as Neurooncology. He has research interests such as phase one, two, three, and four clinical studies and new drug development; therefore Dr. Kavan is a CCTG NCIC representative helping to conduct clinical trials at McGill University, within Quebec, and the rest of Canada.